Cargando…

Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions

OBJECTIVE: To report on the incidence of nab-paclitaxel hypersensitivity reactions (HSRs) in patients with prior taxane HSR. METHODS: From 2005 to 2015, all patients who received nab-paclitaxel for a gynecologic malignancy were identified. Chart abstraction included pathology, prior therapy, indicat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maurer, Kathryn, Michener, Chad, Mahdi, Haider, Rose, Peter G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447141/ https://www.ncbi.nlm.nih.gov/pubmed/28541630 http://dx.doi.org/10.3802/jgo.2017.28.e38

Ejemplares similares

Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel()
por: de Leon, Maria C.B., et al.
Publicado: (2013)

Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review
por: Pellegrino, Benedetta, et al.
Publicado: (2017)

Hypersensitivity Reactions to Platinum Agents and Taxanes
por: Tsao, Lulu R., et al.
Publicado: (2021)

Is nab-paclitaxel better than conventional taxanes as neoadjuvant therapy for breast cancer? A meta-analysis
por: Li, Yong, et al.
Publicado: (2020)

Nab-paclitaxel-associated photosensitivity: report in a woman with non-small cell lung cancer and review of taxane-related photodermatoses
por: Beutler, Bryce D., et al.
Publicado: (2015)

Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis
por: Liu, Miao, et al.
Publicado: (2021)

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors
por: Munster, Pamela N., et al.
Publicado: (2022)

nab-Paclitaxel for the treatment of pancreatic cancer
por: Kim, George
Publicado: (2017)

Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel
por: Kokubu, Hiraku, et al.
Publicado: (2023)

Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer
por: Wan, Rui, et al.
Publicado: (2023)

Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life
por: Palumbo, Raffaella, et al.
Publicado: (2015)

nab-Paclitaxel dose and schedule in breast cancer
por: Martín, Miguel
Publicado: (2015)

Neoadjuvant nab-paclitaxel in the treatment of breast cancer
por: Ueno, Naoto T., et al.
Publicado: (2016)

Successful Treatment of Advanced Thymic Carcinoma with Carboplatin plus nab−Paclitaxel and Maintenance Monotherapy with nab−Paclitaxel: Two Case Reports
por: Araya, Tomoyuki, et al.
Publicado: (2020)

Risk Factors of Hypersensitivity to Carboplatin in Patients with Gynecologic Malignancies
por: Tai, Yu-Hsiao, et al.
Publicado: (2017)

First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report
por: Funaishi, Kunihiko, et al.
Publicado: (2017)

Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer
por: Al-Hajeili, Marwan, et al.
Publicado: (2014)

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
por: Alvarez, R, et al.
Publicado: (2013)

A Case of Stress Cardiomyopathy With Nab-Paclitaxel Infusion
por: Singh, Harjinder, et al.
Publicado: (2023)

Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
por: Zong, Yuan, et al.
Publicado: (2020)

Low Intensity Ultrasound as an Antidote to Taxane/Paclitaxel-induced Cytotoxicity
por: Amaya, Celina, et al.
Publicado: (2022)

Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
por: Chen, Shuling, et al.
Publicado: (2023)

Hypersensitivity Reaction and Tolerance Induction to Ethambutol
por: Cernadas, Josefina Rodrigues, et al.
Publicado: (2013)

Tolerance of the mRNA COVID-19 vaccines in patients with reported taxane reactions
por: Alenazy, Leila A., et al.
Publicado: (2022)

Ranitidine and the incidence of hypersensitivity reactions to paclitaxel: A retrospective cohort study
por: Haine, Anouk I., et al.
Publicado: (2022)

Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval
por: Yamamoto, Yutaka, et al.
Publicado: (2011)

Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer
por: Vishnu, Prakash, et al.
Publicado: (2011)

Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
por: Blais, Normand, et al.
Publicado: (2014)

Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer
por: De Luca, Rossella, et al.
Publicado: (2018)

Nab-paclitaxel - Third-line chemotherapy in advanced gallbladder cancer
por: Patel, Amol, et al.
Publicado: (2020)

Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers
por: Sen, Shiraj, et al.
Publicado: (2018)

Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration
por: Chen, Nianhang, et al.
Publicado: (2015)

Retrospective analysis of the effectiveness and tolerability of nab‐paclitaxel in Chinese elderly patients with advanced non‐small‐cell lung carcinoma
por: Wang, Shuhang, et al.
Publicado: (2020)

Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study
por: Ueno, Makoto, et al.
Publicado: (2021)

Reply: ‘Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'
por: Alvarez, R, et al.
Publicado: (2014)

Erratum: Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
Publicado: (2014)

nab-Paclitaxel in Combination with Carboplatin for a Previously Treated Thymic Carcinoma
por: Makimoto, Go, et al.
Publicado: (2014)

nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors
por: Soliman, Hatem H
Publicado: (2016)

nab-Paclitaxel for the treatment of breast cancer: an update across treatment settings
por: Brufsky, Adam
Publicado: (2017)

Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5vcmsjknc0r5c1ncj71j67d3m5